Medical
-
Ethris has announced topline data from a Phase 2a challenge study of ETH47 mRNA-based antiviral in adults with mild-to-moderate asthma. According to Ethris, the trial demonstrated that ETH47 “was safe, well tolerated and showed antiviral… Read more . . .
-
The Dutch Central Committee on Research Involving Human Subjects has approved Abera Bioscience’s application for a Phase 1 clinical trial of its Ab-01.12 intranasal pneumococcal vaccine, the company said. According to Abera, the dose escalation… Read more . . .
-
Tiziana Life Sciences has announced that the Phase 2a INFORM-MS study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis met both of its primary endpoints, demonstrating significant reduction in microglial activation at Week… Read more . . .
-
Merck has announced the initiation of the Phase 3 ENHANCE-3 study of Ohtuvarye ensifentrine inhalation suspension, which is expected to enroll 2,136 COPD patients and will evaluate Ohtuvarye for the prevention of exacerbations. Merck acquired… Read more . . .
-
Following soon after United Therapeutics’ announcement that the FDA had cleared an IND for a Phase 2 trial of the company’s treprostinil SMI in patients with PH-COPD, the company has announced an IND clearance for… Read more . . .
-
Phase 2a trial of AerTherapeutics’ nebulized fexlamose failed to meet primary or secondary endpoints
Aer Therapeutics has announced that a Phase 2a trial of fexlamose (AER-01) inhalation solution in patients with moderate-to-severe COPD failed to meet primary or secondary endpoints and also demonstrated an increased incidence of adverse events… Read more . . .
-
Blue Lake Biotechnology announced that it has received a $5 million grant from the Gates Foundation to support the addition of younger children to a Phase 1/2a clinical trial of its BLB201 nasal vaccine against… Read more . . .
-
Israeli biotech Nano24 announced that a Phase 2b trial of nebulized EXO-CD24 exosomes in patients with acute respiratory distress syndrome met its primary endpoint, with 85% of patients who received EXO-CD24 having an SpO2/FiO2 >315… Read more . . .
-
According to United Therapeutics, the FDA has cleared the company’s IND for the 16-week Phase 2 SUMMIT trial of treprostinil SMI in patients with pulmonary hypertension associated with COPD, which is expected to enroll approximately… Read more . . .
-
Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy.… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


